Background
1 The Respondent (the Commissioner) has applied for orders requiring the Applicant (MAHPL) to discover, and to take all reasonable steps available to it to obtain, documents in the relevant categories. Initially the Commissioner sought six categories of documents, but only pressed the application in relation to categories 3, 4 and 6 of his application.
2 By two proceedings, MAHPL appeals against objection decisions made by the Commissioner disallowing objections against certain assessments issued for the years ended 31 December 2009 to 31 December 2020 (the Assessments). The Assessments denied deductions for interest costs incurred by MAHPL's subsidiary, Mylan Australia Pty Ltd (MAPL), on a promissory note referred to as "PN A2", issued by MAPL to another Mylan Group entity, Mylan Luxembourg 1 S.a.r.l (Lux 1) and on a subsequent promissory note referred to as "PN A4", issued by MAPL. PN A4 is not relevant to the issues that arise on the present application.
3 PN A2 formed part of the financing by which MAPL acquired the shares in Alphapharm Pty Ltd (Alphapharm) on 2 October 2007. That acquisition was part of the broader acquisition of the "Merck" worldwide generic pharmaceutical group by Mylan Inc (Mylan), then the ultimate parent of MAHPL. MAHPL is the head of the tax consolidated group formed under Pt 3-90 of the Income Tax Assessment Act 1997 (Cth).
4 The principal of PN A2 was set at 75% of the value of Alphapharm, subsequently fixed at AUD923,205,336. The interest rate was originally floating, but at some point it was fixed at 10.15% per annum with retroactive effect from 2 October 2007. The evidence in the proceeding includes a journal entry made in early October 2008 giving effect to this fixed interest rate retroactively.
5 The Assessments issued by the Commissioner disallowed interest deductions in reliance on determinations made under Pt IVA of the Income Tax Assessment Act 1936 (Cth) (the 1936 Act). The Commissioner previously also relied, but no longer relies, on transfer pricing provisions to support the Assessments.
6 On 31 May 2023, the two proceedings were fixed for trial on 9 October 2023 on an estimate of 10 days. The matter was fixed for trial shortly after a case management hearing was held on 5 May 2023, at which the date of 9 October 2023 was discussed. At the time of that hearing, the Commissioner had foreshadowed (but had not yet made) the present discovery application. The Commissioner did not submit that the matter should not be fixed for trial on 9 October 2023 due to the foreshadowed discovery application. Nor did the Commissioner press the present application, which was made on 25 May 2025, on the basis that the trial ought to be vacated if that was necessary to enable its discovery request to be met.
7 It is necessary to say something briefly about the procedural chronology, given the lateness of the present application relative to the forthcoming trial, and having regard to the extensive period over which the Commissioner has been able to obtain documents, either by exercising his statutory powers, or by making requests for information (RFIs), as part of the investigation, audit and objection periods which preceded the issuing of the Assessments.
8 The Commissioner's investigation commenced in November 2009 and progressed to an audit in early August 2012. The Commissioner made at least 18 requests for information, and over 1,500 documents were produced. The Court was taken to some requests, and the responses to those requests, in the course of argument.
9 The Assessments were issued on 27 April 2021 for the 2009 to 2019 tax years (the 2009-2019 Assessments). Another Assessment, for the 2020 tax year, was issued on 28 February 2022 (the 2020 Assessment).
10 MAHPL lodged notices of objection on 4 June 2021, in respect of the 2009-2019 Assessments, and on 6 April 2022, in respect of the 2020 Assessment.
11 On 14 October 2021, MAHPL issued notices, in relation to the 2009-2019 Assessments, under s 14ZYA of the Taxation Administration Act 1953 (Cth) (TAA), the effect of which was relevantly to compel the Commissioner to determine the objections within 60 days, with a decision disallowing the objection deemed to have been made if no decision has been made within 60 days. MAHPL issued a further s 14ZYA notice in relation to the 2020 Assessment on 8 June 2022.
12 The Commissioner made a decision disallowing the objections to the 2009-2019 Assessments on 13 December 2021, just over six months after the objections were lodged on 4 June 2021. The Commissioner made a further decision disallowing the objection to the 2020 Assessment on 28 July 2022. The two decisions are in substantially identical terms and are treated in these reasons as one objection decision.
13 The Commissioner's objection decision identified, as the primary scheme for the purposes of the application of Pt IVA, a scheme involving the incorporation of the two Australian subsidiaries, MAHPL and MAPL. The Commissioner's primary counterfactual involved Alphapharm becoming a part of the Mylan Group without any Australian subsidiaries being incorporated, but by the acquisition of Alphapharm's parent company, Merck Generics Group B.V. (MGG BV). The Commissioner's objection decision also identified two alternate schemes, and two alternate counterfactuals, both allowing for the incorporation of the Australian subsidiaries, but providing for a lower gearing ratio, in other words, more equity and less debt. In respect of one of the alternate counterfactuals, the Commissioner posited the intra-group borrowing (ie PN A2) being replaced with external debt funding, and in the other, by intra-group borrowings, but for a lesser amount, and on different terms.
14 The Commissioner's objection decision referred to two counterfactuals put forward by MAHPL during the audit. The two further counterfactuals developed by the Commissioner were said (in the objection decision) to draw on the counterfactuals identified by MAHPL and to have been identified by the Commissioner in reviewing the audit decision and in considering MAHPL's contentions in respect of Pt IVA.
15 The principal proceeding was then commenced on 22 December 2021, with a further proceeding commenced (in respect of the 2020 Assessment), on 13 September 2022.
16 The Commissioner's Appeal Statement in the principal proceeding was filed on 14 February 2022 and MAHPL's Appeal Statement was filed on 28 February 2022. The secondary and tertiary schemes and counterfactuals set out in the Commissioner's Appeal Statement accorded with the alternatives identified and set out in the objection decision in December 2021.
17 While the Commissioner amended his Appeal Statement in May 2023 to remove reliance on transfer pricing provisions, it is otherwise unchanged since it was filed.
18 MAHPL's lay evidence comprises two affidavits. The first is an affidavit of Paul Campbell dated 4 August 2022. Mr Campbell is the Senior Vice President, Controller and Chief Accounting Officer at Viatris Inc, MAHPL's current ultimate parent company. Mr Campbell's affidavit largely exhibits valuation documents, including drafts, prepared by PwC and which go back to 24 August 2007. A complete draft valuation was issued on 30 May 2008 and the final valuation was issued on 9 February 2009.
19 The second lay affidavit is an affidavit of Thomas Salus, Deputy Global General Counsel of Mylan and Assistant Secretary of Viatris Inc. Mr Salus's affidavit says nothing of substance, but exhibits 205 documents as forming "part of the records belonging to and maintained by Viatris and its related entities". The Commissioner relies on the fact that many documents exhibited by Mr Salus are, on their face, documents of Mylan (then the relevant parent entity) as distinct from being documents of the Australian subsidiaries. The Commissioner contrasted the production, by MAHPL in its lay evidence, of documents of the then-parent company, with the responses given to various of the Commissioner's document and information requests, which carefully (as the Commissioner sees it) did not produce parent company documents in answer to queries directed to the Australian subsidiaries.
20 Given the limited ambit of the lay affidavits, it appears clear that the trial will be contested on the documentary record and on the expert evidence.
21 MAHPL filed an affidavit of Kevin Glenn, a US tax attorney, dated 2 August 2022, which annexed Mr Glenn's expert report (Glenn I). The expert retained by the Commissioner, Harry Rosenbloom, prepared a responsive report, annexed to an affidavit dated 29 November 2022 (Rosenbloom). Mr Glenn prepared a reply report, dated 10 April 2023 (Glenn II). This body of expert evidence addressed the US tax consequences of the transaction as it occurred, as well as the relative tax position of the counterfactual transactions.
22 MAHPL also filed expert reports of Terence Stack dated 5 August 2022 (Stack I), and Mozammel Ali dated 10 August 2022 (Ali I).
23 The Commissioner filed a report of David Bernard responding to Stack I and parts of Ali I dated 8 December 2022 (Bernard I) and a report of Gregory Johnson dated 15 February 2023 responding to parts of Stack I and Ali I (Johnson I).
24 MAHPL filed reply reports of Mr Stack (Stack II) and Mr Ali (Ali II), both dated 11 April 2023.
25 On the present application, the parties relied on affidavits of their solicitors, which largely concerned the chronology above, and the details of the information and documents sought by the Commissioner, and the responses the Commissioner received to those requests.
26 MAHPL also put on evidence of Daniel Slater, a special counsel at MinterEllison, MAHPL's solicitors, stating that, if orders were made in the terms sought by the Commissioner (which then comprised six categories), the resultant discovery exercise would cost "many hundreds of thousands of dollars", and would take at least 90 days to complete. Mr Slater also stated that the "Mylan Group" (as that term is used in some proposed categories) comprised 22 entities from 29 January 2007 to 2 October 2007, and an additional 38 entities from 2 October 2007 to 31 December 2007.
27 The Commissioner gave notice that he was pressing his application only in respect of three of the six categories on the weekend before the hearing, and (not surprisingly) there was no evidence regarding how much time or cost would be saved by the narrowing of the application. There was no application to cross-examine Mr Slater on his time and cost estimates.